Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
about
Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsNovel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.Pharmacological management of polycystic kidney disease.An overview of quinoline as a privileged scaffold in cancer drug discovery.
P2860
Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@ast
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@en
type
label
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@ast
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@en
prefLabel
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@ast
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@en
P2093
P2860
P356
P1476
Bosutinib: a second-generation ...... chronic myelogenous leukemia.
@en
P2093
Lindsay Stansfield
Thomas E Hughes
Tracey L Walsh-Chocolaad
P2860
P304
P356
10.1177/1060028013503124
P407
P577
2013-12-01T00:00:00Z